Lineage Cell Therapeutics, Inc.
Extract: Charter Amendment (Plain English Desc) from a 8-K on 08/12/2019   Download
SEC Document
SEC Filing

On August 9, 2019, BioTime, Inc. (the “Company”) amended Article I of its Restated Articles of Incorporation to change its name from “BioTime, Inc.” to “Lineage Cell Therapeutics, Inc.” The amendment and name change were completed through a merger of the Company’s wholly owned subsidiary, Lineage Cell Therapeutics, Inc., with and into the Company pursuant to Section 1110(d) of the California Corporations Code (the “Code”).